MARch 24/26, 2014hotel Nh Vittorio Veneto

Rome - Italy

PROGRAM

“...in the heart of Rome”

ORGANIZING COMMITTEE ANDORGANIZING SECRETARIAT

ORGANIZING COMMITTEE

• Laura calabresiMilan, Italy

• Franco BerniniParma, Italy

• Geesje M. Dallinga-ThieAmsterdam, The Netherlands

• Arnold von EckardsteinZurich, Switzerland

• Kerry-Anne Rye Sydney, Australia

• Alan TallNew York, U.S.A.

ORGANIZING SECRETARIAT

Via Roma, 10 • 16121 Genova • ItalyTel. (+39) 010 553591 • Fax (+39) 010 5535970E-mail iasworkshophdl@aristea.com • Web www.aristea.com

SUMMARY

PROGRAMMONDAY, MARch 24, 2014 4TUESDAY, MARch 25, 2014 6WEDNESDAY, MARch 26, 2014 9

POSTER SESSION 11

REGISTRATIONREGISTRATION FEES 18REGISTRATION 18NAME chANGES 18ON-SITE PAYMENT 18

SCIENTIFIC INFORMATIONchAIRPERSONS AND SPEAKERS GUIDELINES 19AUDIOVISUALS POWERPOINT PRESENTATION INSTRUcTIONS 19ORAL PRESENTATION 20POSTER PRESENTATION 20

GENERAL INFORMATIONcONGRESS VENUE 21hOW TO REAch ThE cONGRESS VENUE 21AccOMMODATION 21REGISTRATION DESK 21OFFIcIAL LANGUAGE 21PASSPORT AND VISA 22INSURANcE 22BADGE 22MOBILE PhONES 22cERTIFIcATES OF ATTENDANcE 22

SPEAKERS AND CHAIRPERSONS 23

PROGRAMMONDAY, MARCH 24, 2014

14.00 WELCOME

Chairpersons: A.L. Catapano, G. Dallinga-Thie

14.30 Plasma levels of high-density lipoprotein cholesterol and risk of symptomatic gallstone disease: a Mendelian randomization studyA. Tybjaerg-Hansen (Denmark)

14.55 Mining the genome for lipid genesJ.A. Kuivenhoven (The Netherlands)

ORAL COMMUNICATIONS

15.20 O 01 Mutations in ABcA8 result in hDL deficiency and cholesterol efflux defects - R. Singaraja (Singapore)

15.35 O 02 Extreme Ends Approach Identifies Novel eQTL Genes for Low hDL-c and Metabolic Abnormalities - P.P. Laurila (Finland)

15.50 O 03 Identification and Analysis of hDL Binding Recombinant Antibodies from Synthetic scFv-antibody Library - J. Lövgren (Finland) 

16.05 coffee break

SESSION 1. EPIDEMIOLOGY AND GENETICS OF HDL 14.30/16.05

4

PROGRAMMONDAY, MARCH 24, 2014

Chairpersons: C. Fernandez-Hernando (U.S.A.), D. Kardassis (Greece)

16.30 miRNA Regulation of HDL metabolismC. Fernandez-Hernando (U.S.A.)

16.55 Nuclear Receptor Regulation of HDL MetabolismA. Moschetta (Italy)

ORAL COMMUNICATIONS

17.20 O 04 changing hDL Protein composition Modulates Early Stages of Breast cancer Development - H. Quesada (Spain)

17.35 O 05 Transport of hDL through endothelial cells - D. Perisa (Switzerland)

17.50 O 06 hepatic AcAT2 Knock Down Increases ABcA1 and Modifies hDL Metabolism in Mice - M. Pedrelli (Sweden)

18.05 Welcome cocktail

SESSION 2. REGULATION OF HDL 16.30/18.05

5

PROGRAMTUESDAY, MARCH 25, 2014

Chairpersons: L. Calabresi (Italy), S. Davidson (U.S.A.)

09.00 Translating apolipoprotein high-resolution structures from lipid-free to lipid-boundS. Davidson (U.S.A.)

09.25 Structure and function of apoM, the carrier of sphingosine-1-phosphate in HDLB. Dahlback (Sweden)

ORAL COMMUNICATIONS

09.50 O 07 Phosphatidylserine is a key component of hDL determining its biological function - A. Kontush (France)

10.05 O 08 Role of LpX in the development of renal disease in LcAT deficiency - A. Ossoli (Italy)

10.20 O 09 Serum Amyloid A is a Unique hDL Apolipoprotein with Atheroprotective Potential: Its Dissociation from hDL is Essential and Impaired by Lipid Oxidation - J. Ancsin (U.S.A.)

10.35 Coffee break

Chairpersons: F. Bernini (Italy), J. Parks (U.S.A.)

11.00 Intracellular cholesterol transport for efflux to HDL acceptorsE. Ikonen (Finland)

11.25 The role of ABCA1 in cholesterol metabolism and atherosclerosisJ. Parks (U.S.A.)

SESSION 3. HDL STRUCTURE-FUNCTION RELATIONSHIP 09.00/10.35

SESSION 4. HDL - CHOLESTEROL HOMEOSTASIS 11.00/12.35

6

PROGRAMTUESDAY, MARCH 25, 2014

ORAL COMMUNICATIONS

11.50 O 10 Regulation Of hDL On hematopoietic Stem/Progenitor cells In Atherosclerosis Requires SR-BI Expression - Y. Feng (Belgium)

12.05 O 11 Absence of PLTP function in SR-BI Knockout Mice Shifts Lipids from hDL toVLDL/LDL and Reduces Atherosclerosis - R.J. van der Sluis (The Netherlands)

12.20 O 12 ApoE3[K146N/R147W] Acts as a Dominant Negative apoE Form that Prevents Remnant clearance and Inhibits the Biogenesis of hDL - V. Zannis (Greece)

12.35 Lunch and Moderated Poster Sessions

Chairpersons: G. Francis (Canada), D. Norata (Italy)

14.30 Altered ABCA1 expression by intimal smooth muscle cells and effects on foam cell formation in human atherosclerosisG. Francis (Canada)

14.55 Vascular effects of HDL in patients with cardiovascular diseaseU. Landmesser (Switzerland)

ORAL COMMUNICATIONS

15.20 O 13 hDL Inhibit Tissue Factor Expression in Endothelial cells and Monocytes - M. Gomaraschi (Italy)

15.35 O 14 Lipoprotein metabolism and transendothelial apolipoprotein A-I transport in mice with an endothelium specific knock-out of ATP binding cassette transporter A1 - R. Hasballa (Switzerland)

15.50 O 15 Fetal hDL-apoM/S1P complex mediates vasoprotective action on the feto-placental endothelium. In Gestational Diabetes Mellitus(GDM) endothelial barrier integrity is impaired - C. Wadsack (Austria) 

16.05 Coffee break

SESSION 5. HDL - VASCULAR BIOLOGY 14.30/16.05

7

PROGRAMTUESDAY, MARCH 25, 2014

Chairpersons: K.A. Rye (Australia), C. Wellington (Canada)

16.30 HDL: good for the heart, good for the brainC. Wellington (Canada)

16.55 Dysfunctional HDLS. Hazen (U.S.A.)

ORAL COMMUNICATIONS

17.20 O 16 Quantification of hDL proteins, cardiac events and mortality in type 2diabetes patients on hemodialysis - T. Weichhart (Austria)

17.35 O 17 Anti-inflammatory Function Of high-density Lipoproteins Via Autophagy Of IkB Kinase - R. Attinkara (Swizerland)

17.50 O 18 Elevated cETP Activity is Associated with Low, Dysfunctional hDL in high cardiovascular Risk South Asians - S. Rashid (Canada)

18.05 EDUCATIONAL GRANTHDL FunctionsK.A. Rye (Australia)

SESSION 6. HDL - DYSFUNCTION AND NOVEL FUNCTIONS 16.30/18.30

8

PROGRAMWEDNESDAY, MARCH 26, 2014

Chairpersons: B.A. Kingwell (Australia), A. von Eckardstein (Switzerland)

09.00 Could HDL therapies play a role in management of type 2 diabetes?B.A. Kingwell (Australia)

09.25 Kinetic studies to elucidate atherogenic dyslipidemiaJ. Boren (Sweden)

ORAL COMMUNICATIONS

09.50 O 19 Genetically Reduced hDL cholesterol and Risk of Type 2 Diabetes: a Mendelian Randomization Study - R. Frikke-Smith (Denmark)

10.05 O 20 Differential Impact of hepatic Deficiency and Total Body Inhibition of Microsomal Triglyceride Transfer Protein on cholesterol Metabolismand Reverse cholesterol Transport in Mice - U. Tietge (Netherlands)

10.20 O 21 Multiple lines of defenses activated by hDLs in pancreatic beta cells - C. Widmann (Switzerland)

10.35 Coffee break

SESSION 7. HDL AND DIABETES 09.00/10.35

9

PROGRAMWEDNESDAY, MARCH 26, 2014

Chairpersons: M. Averna (Italy), A. Remaley (U.S.A.)

11.00 Development of recombinant Lecithin: Cholesterol Acyltransferase for the treatment of cardiovascular disease and Familial LCAT DeficiencyA. Remaley (U.S.A.)

11.25 Is S1P an HDL mimetic for therapy of atherosclerosis?J-R. Nofer (Germany)

ORAL COMMUNICATIONS

11.50 O 22 In vivo assessment of the effect of Tetranectin-ApoA-I infusions on atherosclerosis progression/regression in rabbit carotid arteries - C. Parolini (Italy)

12.05 O 23 Abdominal Aortic Aneurysm Progression Is Limited By hdl Therapy - S. Delbosc (France)

12.20 O 24 Improvement of cell cholesterol Trafficking-related Lipoprotein Functions in Rheumatoid Arthritis patients treated with AdalimumabN. Ronda (Italy)

12.35 KEY NOTE LECTUREInhibition of CETP: an overviewG.K. Hovingh (The Netherlands)

13.00 closing

SESSION 8. HDL - TARGETED THERAPIES 11.00/13.10

10

P 01 ApoA-I deficiency in apoE-KO mice severely alters lymph nodes and modulates T lymphocyte subsetsM. Busnelli, F. Sala, S. Manzini, G.S. Ganzetti, C. Parolini, F. Dellera, E. Scanziani, L. Arnaboldi, C.R. Sirtori, G.D. Norata, G. Chiesa

P 02 ApoA-I depletion in chow-fed apoE-KO mice severely enhances aortic and coronary atherosclerosis developmentG.S. Ganzetti, M. Busnelli, C. Parolini, S. Manzini, F. Dellera, C.R. Sirtori, G. Chiesa

P 03 Endothelial Lipase Attenuates Vasorelaxing capacity of hDLS. Opresnik, S.P. Rao, A. Hrzenjak, S. Hallström, A. Kozina, I. Sreckovic, Ch. Wadsack,M. Holzer, G. Marsche, R. Birner-Gruenberger, T. Stojakovic, H. Scharnagl, S. Frank

P 04 Exogenous Glucocorticoid-induced Immunosuppression Does Not Normalize Atherosclerosis Susceptibility in hDL Deficient MiceM. Hoekstra, R.J. van der Sluis, T.J.C. Van Berkel, M. Van Eck

P 05 hDL dysfunction in patients with chronic renal failure: activation of pro-inflammatory receptors in vascular smooth muscle cells by serum amyloid AN. Prüfer, M. Schuchardt, J. Prüfer, M. van der Giet, M. Tölle

P 06 hDL protects macrophages against er-stress-induced apoptosis in an SR-BI dependent mannerB. Trigatti

P 07 high density lipoproteins exert pro-inflammatory effects on macrophages via IKK2- and NIK-independent NF-?B activationE.P.C. van der Vorst, K. Theodorou, I. Wolfs, C. Bursill, K.A. Rye, M. van Eck, J. Plat, M. Hoeksema, D. Koonen, S. Tas, M.P.J. de Winther, E.A.L. Biessen, M.M.P.C. Donners

P 08 hyperuricemia Is Associated With A Low Plasma concentration Of hDLParticlesAnd Increased Apo AI Fractional catabolic Rates In New Zealand White RabbitsM. Martínez-Ramírez, R. Bautista-Pérez, O. Pérez Méndez

P 09 Inhibition of mtor down-regulates scavenger receptor, class B, type I expressionand impairs endothelial cell migration and nitric oxide productionS. Fruhwürth, H. Stangl

P 10 Lipid ratios as predictors of subclinical atherosclerosisS. Novo, F. Macaione, F.P. Guarneri, E. Corrado, S. Evola, G. Novo

P 11 Prognostic value of LDL/hDL cholesterol ratio in patients undergoing coronary stentingS. Novo, F. Macaione, F.P. Guarneri, E. Corrado, S. Evola, G. Novo

HDL AND VASCULAR BIOLOGY

11

POSTER SESSION

P 12 Diabetes reduces the protective effect of hDL against cardiomyocyte death induced by oxidative stressJ. Brinck, R.W. James, M.A. Frias

P 13 Effect of Ezetimibe added to ongoing Statin therapy in stable ischemic heartdisease patients with type 2 Diabetes mellitusT. Naka, K. Takahashi, T. Arii, M. Ohyanagi

P 14 Evaluation Of Serum cholesterol Efflux capacity In Diabetic compared To healthy SubjectsM.P. Adorni, E. Favari, N. Ronda, F. Zimetti, D. Ardigò, L. Franzini, M. Manfredini, S. Calandra , A.F.G. Cicero, G.B. Vigna, I. Zavaroni, F. Bernini

P 15 hDL anti-inflammatory function in relation to vascular complications in type 2 diabetes mellitusR. Lemmers, M. Mulder, W. Dik, A Verhoeven, M. van Hoek, L. Lieverse, E Sijbrands

P 16 Lipoprotein Profiles in South Asian and caucasian Type 2 Diabetes PatientsR. Yahya, S. Jainandunsing, R. Biharie, L. van der Zee, J. Touw, F. de Rooij, E. Sijbrands, A. Verhoeven, M.T. Mulder

P 17 Association Between Psoriasis and AtherosclerosisA.H.A. Alobaidi, I.A.M.A.M. Alsamarai

P 18 Association of hDL subfractions with coronary atherosclerosis in patients receiving statinsN. Artemeva, E.Utkina, O. Afanasieva, Yu. Matchin, A. Burdeynaya, I. Adamova, M. Ezhov, S. Pokrovsky

P 19 Do apolipoproteins improve coronary risk prediction in subjects with cardiometabolic risk?F. Gianfagna, G. Veronesi, L. Guasti, L.E. Chambless, P. Brambilla, R. Borchini,T. Abate, L. Turetta, G. Corrao, G. Mancia, G. Cesana, M.M. Ferrario

P 20 high density lipoprotein cholesterol levels are an independent predictor of the progression of chronic kidney diseaseA. Baragetti, G.D. Norata, C. Sarcina, F. Rastelli, L. Grigore, K. Garlaschelli, P. Uboldi,I. Baragetti, C. Pozzi, A.L. Catapano

HDL EPIDEMIOLOGY

HDL AND DIABETES

POSTER SESSION

12

P 21 Predictive value of hDL subfractions on cardiovascular risk and mortalityResults from the LURIc studyB. Genser, P. Pagel, M. Kleber, G. Silbernagel, H. Scharnagl, T. Grammer, V. Pfahlert, W. März

P 22 Relevance of hDL-cholesterol in Metabolic SyndromeM. Menegatti, C Ferrari, M. Bellan, C. Marconi, F. Caldera, G. Pogliani, G.P. Fra, G.P. Carnevale Schianca, M. Pirisi

P 23 Smaller hDL Subclasses Are Associated with Increased Mortality in chronicKidney Disease and with Increased Risk of cardiovascular Morbidity Following Renal TransplantationA. Zeljkovic, V. Spasojevic-Kalimanovska, J. Vekic, Z. Jelic-Ivanovic, N. Bogavac-Stanojevic, A. Peco-Antic, S. Simic-Ogrizovic, S. Spasic

P 24 A potential role of LRP1 in human hDL metabolism. Identification and characterizationof the first LRP1 mutations in individuals with extremelylow hDL cholesterol levelsF. Oldoni, R.J. Sinke, M.M. Motazacker, G.M. Dallinga-Thie, G.K. Hovingh, D. Hui, J.A. Kuivenhoven

P 25 Gene-expression profiling of lymph nodes reveals that apoA-I deficiency in apoE-KO mice induces a dramatic activation of the immune responseF. Dellera, S. Manzini, M. Busnelli, C. Parolini, M. Chiara, G.S. Ganzetti, C.R. Sirtori, D.S. Horner, G. Chiesa

P 26 Is PON1 Q192R Polymorphism Risk Factor for Diabetic complications-Preliminary StudyZ. Rasic-Milutinovic, M. Zec, G. Perunicic-Pekovic, B. Rovcanin, I. Novakovic

P 27 PON1 192 polymorphism and lipid profile in hypertensive patients withor without cKDM. Zec, G. Perunicic-Pekovic, Z. Rasic-Milutinovic, B. Rovcanin, I. Novakovic

P 28 Docosahexaenoic acid modulates the expression of intestinal microRNAs involved in lipid metabolismA. Dávalos, B. García-Carrasco, J. Gil-Zamorano, R. Martin1, L. Daimiel, S. Malaguti, E. Iglesias-Gutiérrez2, F. Visioli

HDL GENETICS

HDL REGULATION

POSTER SESSION

13

P 29 Effects of a lactobacillus casei shirota containing probiotic drink on lipid and glucose metabolism in patients with impaired glucose regulationL. Kedenko, E. Hackl, C. Mühlberger, C. Gemeier, M. Leitner, I. Kedenko, A. Kautzky-Willer, B. Paulweber

P 30 Effect of Tamoxifen and Raloxifene on hDL Biochemical Properties and Metabolism in MiceM.E. Fernandez-Suarez, J.C. Escola-Gil, O. Pastor, A. Davalos, F. Blanco-Vaca, M.A. Lasuncion, J. Martinez-Botas, D. Gomez-Coronado

P 31 Endoplasmic reticulum stress impairs abca1 expression and alters cholesterol metabolism in hepatic cellsC. Röhrl, K. Eigner, K. Winter, M. Korbelius, S. Obrowsky, D. Kratky, W.J. Kovacs, H. Stangl

P 32 Expression Patterns of hDL Genes During Intestinal InflammationE.Thymiakou, D. Kardassis

P 33 Gene regulation of apolipoprotein e in macrophagesV.G. Trusca, D. Kardassis, M. Simionescu, A.V. Gafencu

P 34 Is c/EBP-? a Novel Target to Rescue the Attenuated Apolipoprotein A-I Production During ER Stress and Inflammation?S.E. van der Krieken, H.E. Popeijus, M. Konings, S. Dullens, R.P. Mensink, J. Plat

P 35 Lipid profile in a population of young children with atopic dermatitisC. Pederiva, G.Pecora, E. D’Auria, G.Radaelli, E.Riva, M.Giovannini

P 36 Olive oil polyphenols promote the cholesterol efflux capacity of hDL byimproving its physical-chemical properties (a randomized trial)Á. Hernáez, S. Fernández-Castillejo, M. Farràs, Ú. Catalán, I. Subirana, M. del Carmen López-Sabater, R. Solà, D. Muñoz-Aguayo, A. Gelabert-Gorgues, Ó. Diaz-Gil, K. Nyyssönen, H.F. Zunft, Rafael

P 36 Inhibition of secretory phospholipase A2 (sPLA2) caused rapid changes in plasmabis hDL composition and function in apoE* Leiden x hcETP mice and reduced the

ex-vivo enzyme effects: potential impact in its athero-protective propertiesE. Hurt-Camejo, G. Camejo, B. Rosengren, M. Wågberg, D. Karlsson, M. Brusberg

P 37 Alterations in antioxidant activity and subfraction distribution of hDLin patients with systemic lupus erythematosusG. Paragh, K. Gaál, H. L?rincz, M. Harangi, V. Borbás, T. Tarr, P. Fülöp, I. Seres

HDL STRUCTURE-FUNCTION

POSTER SESSION

14

P 38 Anti-Psoriatic Therapy Recovers high-Density Lipoprotein composition and Function Independent of Serum hDL-cholesterol LevelsG. Marsche, P. Wolf, M. Holzer

P 39 Apolipoprotein M Modulates Erythrocyte Efflux and Urinary Excretion of Sphingosine-1-PhosphateI. Sutter, R. Park, A. Othman, L. Rohrer, T. Hornemann, M. Stoffel, O. Devuyst, A. von Eckardstein

P 40 Deacreased antioxidant properties of hDL and altered lipid subfraction profile in children with Smith-Lemli-Opitz syndromeI. Seres, H. L?rincz, M. Harangi, A.V. Oláh, G. P. Szabó, S. Somodi, G. Paragh

P 41 Effect of ApoE Isoforms and carboxy-Terminal Truncated Forms on Interactions and Activation Properties with PLTPI. Dafnis, J. Metso, C. Ehnholm, V.I. Zannis, M. Jauhiainen, A. Chroni

P 42 Effects of rapid weight loss on hDL structure and functionalityE. Zvintzou, G. Skroubis, A. Chroni, P-I.a Petropoulou, C. Gkolfinopoulou, G. Sakellaropoulos, D. Gantz, I. Mihou, F. Kalfarentzos, K.E. Kypreos

P 43 Evaluation of cholesterol Efflux capacity (cEc), as an Index of hDLFunctionality, in Pediatric Patients with cholesteryl Ester Storage Disease (cESD)E. Favari, P. Cagliero, F. Zimetti, M.P. Adorni, F. Bernini, P. Brunatti, O. Guardamagna

P 44 Fatty acid composition of plasma lipids in LcAT deficient patients supports the formation of AcAT2-derived cholesteryl esters in humansS. Simonelli, P. Risè, C. Galli, L. L. Rudel, G. Franceschini, L. Calabresi

P 45 hDL does not influence the polarization of human monocytes toward an alternative phenotypeS. Colin, M. Fanchon, L. Belloy, A.E. Bochem, C. Copin, B. Derudas, E. Stroes, G.K. Hovingh, J.A. Kuivenhoven, G.M. Dallinga-Thie, B. Staels, G. Chinetti-Gbaguidi

P 46 hDL Proteins as Predictors of cardiovascular Risk and Mortality in Diabetic Patients on hemodialysisC. Kopecky, B. Genser, W. März, C. Wanner, M.D. Säemann, T. Weichhart

P 47 high density lipoproteins are low and dysfunctional in septic shockD. Diallo, S. Tanaka, C. Geneve-Coache, N. Zappela, A. Harrois, S. Hamada, J. Duranteau, O. Meilhac

P 48 Impaired cholesterol Efflux capacity and Vasculoprotective Function of hDL in heart Transplant RecipientsN. Singh, F. Jacobs, D.J. Rader, J. Vanhaecke, J. Van Cleemput, B. De Geest

POSTER SESSION

15

P 49 Impaired cholesterol efflux into hDL2 in metabolic syndromeT. Paavola, S. Kuusisto, S. Kakko, T. Kangas-Kontio, J. Metso, M. Jauhiainen, M. Hannuksela, M. Savolainen, T. Salonurmi

P 50 In vivo acute systemic inflammation affects hDL cholesterol efflux capacityF. Zimetti, E. Favari, N. Ronda, F. Bernini, M. Gomaraschi, S. Simonelli, L.Calabresi,M. Pirro, G. Lupattelli

P 51 Isolation and proteomic analysis of apo A-I containing lipoprotein particles, in the density range of hDL, in Nasal Lavage Fluid, Saliva and PlasmaH. Karlsson, S. Ljunggren, M. Lindahl, B. Ghafouri

P 52 Low concentrations of Sphingosine-1-Phosphates and Plasmalogens in hDL are with coronary Artery Disease and Reduced Anti-apoptotic Activity of high Density LipoproteinsI. Sutter, U. Landmesser, T. Hornemann, A. von Eckardstein

P 53 Methionine Oxidation and Amyloid Fibril Formation by Apolipoprotein A-IG.K.L. Chan, A. Witkowski, S. Jayaraman, G. Cavigiolio

P 54 Peritoneal dialysis and hemodialysis differentially modulate hDL compositionand functionM. Holzer, G. Schilcher, M. Trieb, S. Curcic, A. Rosenkran, G. Marsche

P 55 Reconstituted high Density Lipoprotein (rhDL) Modulates Th1 and Th17Immune Responses and Pro-Inflammatory cytokine Production in a MurineModel of Rheumatoid ArthritisI. Tiniakou, M. van Eck, V.I Zannis, D. Boumpas, P. Verginis, D. Kardassis

P 56 Role of polyphenols against glycation of hDL induced by methylglyoxalT. Bacchetti, I. Turco, G. Ferretti

P 57 Structural and functional changes of hDL in patients with chronic renal failureM. Schuchardt, M. Tölle, T. Huang, N. Prüfer, S. Chebli, U. Tietge, V. Jankowski, M. van der Giet

P 58 The hDL/ Apolipoprotein M (apoM)/Sphingosine-1-phosphate (S1P)-complex and its interaction with the S1P-receptorsC. Frej, K.E. Otteby, B. Dahlbäck

P 59 The Molecular composition and Function of high-Density Lipoprotein is Uniquely Altered after Kidney TransplantationC. Kopecky, M. Haidinger, R. Birner-Grünberger, C. Kaltenecker, G. Marsche, M. Holzer, M. Antlanger, J. Kovarik, J. Werzowa, M. Hecking, M.D. Säemann

P 60 The Role of Lecithin-cholesterol Acyltransferase in Lipopolysaccharide-Induced InflammationP. Petropoulou, J.F.P. Berbée, I. Karagiannides, K.E. Kypreos

POSTER SESSION

16

P 61 Treatment of a compound heterozygous familial hypercholesterolemia patient with lomitapideR. Yahya, E. Favari, S. Bos, R. Vongpromek, L. Van Der Zee, A. Touw, F. Zimetti, M.P. Adorn,F. Bernini, A. Verhoeven, E.J.G. Sijbrands, M.T. Mulder, J.E. Roeters Van Lennep

P 62 Both hepatic Lipase- And Endothelial Lipase-Deficiency Improve Two MajorAntiatherogenic Properties of hDL In Knockout MiceJ. Julve, JC. Escolà-Gil, X. Chen, H. Quesada, D. Santos, J. Metso, M. Tous, M. Jauhiainen, F. Blanco-Vaca

P 63 Endogenous hDL is necessary and sufficient for remodeling of cSL112 in plasmaS.A. Didichenko, A.V. Navdaev, M.O. Spycher, S.D. Wright

P 64 Ezetimibe effects of adding in therapy in a small cohort of overweight patients already in statin therapy: an experience in general practiceV.M. Magro

P 65 hDL Modulates The human Monocyte Phenotype and Its Subclass levels Are Altered In MS PatientsW. Jorissen, JFJ. Bogie, B. van Wijmeersch, L. Freeman, P. Stinissen, M. Mulder, N. Hellings, T. Vanmierlo, AT. Remaley, JJA. Hendriks

P 66 Intravenous, Single-Dose AcP-501 (rhLcAT) is Well-Tolerated and Raises hDL-c in Subjects with coronary Artery DiseaseM. McCarthy, R. Shamburek, R. Bakker-Arkema, B. Auerbach, R. Homan, B. Krause, M. Amar, A. Shamburek, E. Piper, A. Remaley

P 67 Stimulation of hepatic apolipoprotein A-I production by novel thieno-triazolodiazepines: roles of the classical benzodiazepine receptor, PAF receptor and bromodomain bindingH. Kempen, S. Nicklisch, O. Fedorov, P. Filippakopoulos, S. Picaud, S. Knapp

P 68 The effect of different pharmacologic treatments for dyslipidemia on the prevalence and activity of anti-hDL antibodiesJR. Batuca, MC. Amaral, C. Favas, KB. Sokoll, A. Ortiz-Cadenas,I. Garcia-de-La Torre5, A. Nava, A. Oregon-Miranda, K. Kojima, E. Matsuura, L.R. Lopez, PRJ Ames, J. Delgado Alves

P 69 Theobromine-enriched cocoa increases hDL-c: a double blind, placebo controlled cross-over studyJ.C. van Capelleveen, B. van den Bogaard, G.K. Hovingh, R. Draijer, B.J. van den Born

P 70 The PPAR-?/? Agonist GW0742 Promotes Pltp Gene ExpressionK. Chehaibi, L. Cedó, J. Metso, J. Julve, X. Palomer, X. Chen, H. Quesada, D. Santos,M. Vázquez-Carrera, M. Jauhiainen, F. Blanco Vaca, J.C. Escolà-Gil

P 71 Vitamin D and hDL-cholesterol In Obese PatientsE. Stokic, D. Smiljenic, A. Kupusinac, B. Srdic-Galic

POSTER SESSION

17

REGISTRATION FEES

< 35 years Euro 250,00> 35 years Euro 500,00

The Registration Fee includes: name badge, admission to all scientific sessions, congressbag, certificate of attendance, lunch, coffee break, welcome reception and social dinner.Fees include VAT 22%.

REGISTRATION

Registration wiIl be acknowledged by means of a Registration Receipt Notice.

This receipt contains:• registration confirmation;• registration number.

The registration number identifies the participant and shall be quoted in all correspondencebetween the participant and the Organizing Secretariat. The number will also helpregistration upon arrival.

ON-SITE PAYMENT

The payment should be made through:• credit card (American Express / Mastercard / Visa)• cash

REGISTRATION

18

SCIENTIFICINFORMATION

CHAIRPERSONS AND SPEAKERS GUIDELINES

chairpersons and speakers should find their session location as early as possible.They should be in their session room 10 minutes prior the beginning of the session.All speakers are requested to keep strictly to their allocated time.chairpersons should make every effort to avoid delays in the schedule.however, if a speaker does not show up, chairpersons should wait until the publishedtime for the next speaker. Speaker's ready room is located in the Plenary Room and isequipped for pc projection.

• MORNING SESSIONS: please proceed the Speaker’s Ready Room the day before• AFTERNOON SESSIONS: please proceed the Speaker’s Ready Room in the morning

WE REcOMMEND TO PROcEED TO ThE SPEAKER’S READY ROOM AT LEAST2 hOURS PRIOR TO YOUR PRESENTATION.

AUDIOVISUALSPOWERPOINT PRESENTATION INSTRUCTIONS

Each room will be equipped with personal computers for the video presentation.The version used at the congress is Microsoft PowerPoint for Windows 2010. Any file(film, video or image) should be saved in the same data folder as the Power Pointpresentation. If non-standard fonts are used (not included in the operating system –Windows 7 or sup., Office 2010 or sup.), please bring with you the files for their installationtogether with the presentation and hand them into the slide center, informing thetechnicians in due time (at least 2 hours prior your session). If any video is included in thepresentation, please make sure they are in the following formats: .avi, .wmv, .mpeg.We suggest .avi format for your videos, compressing it with the following codecs: DivX, Xvid.Projection size is 4:3 – resolution 1024x768 pixel and 72 dpi.For slides with different format (e.g. 16:9) two black stripes will be projected on the screen.To avoid this we suggest to choose on “page layout” – presentation in 4:3 - when youcreate your PPT presentation.For speakers using Macintosh systems and Keynote-format presentations: you are invited toconvert to the PowerPoint format, or , alternatively, to be at the “Slide center” at least twohours in advance, as to allow this conversion. Should you prefer not to convert to PowerPoint,you might choose to use your personal MAc Pc bringing the VGA ADAPTER with you.

19

SCIENTIFICINFORMATION

ORAL PRESESENTATION

Each presentation will be allowed 10 minutes followed by 5 minutes discussion.

POSTER PRESENTATION

Poster presentations are an important aspect of the IAS Workshop Program.The moderated poster sessions will be held on Tuesday, March 25th during the lunch break.Presenting Authors are requested to be present at their poster from 13.00 to 14.30.

Other Information

The poster size is 100 cm (height) and 70 cm (width).The posters will be displayed in the appropriate spaces, marked by a numbercorresponding to the poster number.The Organizing Secretariat will provide the equipment to post them up.Each poster must be displayed by 9:30 and removed by 18:00, Tuesday, March 25th.The Organizing Secretariat will not be responsible for posters that aren't removed on time.

20

GENERALINFORMATION

CONGRESS VENUE

NH Vittorio Venetocorso D'Italia, 1 • 00198 Roma • Italy

HOW TO REACH THE CONGRESS VENUE

By carGPS coordinates: Latitude: 41.91017402593138 - Longitude: 12.49022126197815

By train Nh Vittorio Veneto is located three kilometers from Termini Station. You can take a bus(line 910) and get off Via Puccini, or you can take the underground (Line A) and get offat Piazza di Spagna, following signs for Villa Borghese.Alternatively, you can take a taxi: the station is five minutes from the hotel.

From Fiumicino Airport:The hotel is located 30 km from the airport. You may take a train to Stazione Termini.From there, you can take the underground (Line A) and get off at either Barberini orSpagna. You may also take a taxi.

ACCOMMODATION

For any information please contact the Travel Agency of Aristea:

Aristea TravelVia Roma, 10 · 16121 Genova · ItalyTel. (+39) 010 553591 · Fax (+39) 010 5535970 • E-mail travel@aristea.com

REGISTRATION DESK

The Registration Desk will open half an hour before the beginning of the sessions andclose half an hour after the end of the sessions.

OFFICIAL LANGUAGE

The official language of the congress is English. Simultaneous translation will NOT be provided.

21

22

GENERALINFORMATION

PASSPORT AND VISA

All foreign visitors must have valid passport. No visas are required for visitors fromWestern European countries, the United States, Japan and many Latin American andBritish commonwealth countries. citizens from other countries must have the requiredvisas. however it is advisable to contact the Italian consulate or Embassy in your countryfor information on visas and health certificates if required.

INSURANCE

The Organizing Secretariat cannot accept responsibility for accident or damage toparticipants or accompanying persons before, during or after the congress. Participantsare urged to make their own arrangements with respect to travel and health insurance.

BADGE

Badges denoting registration status will be given to all participants upon their check-inat the registration desk. Participants will not be admitted to any scientific session withouttheir badge. Should you lose your badge, please go to the Registration Desk for assistance.

MOBILE PHONES

Participants are kindly requested to keep their mobile phones in off position in the roomswhere scientific sessions are being held.

CERTIFICATES OF ATTENDANCE

certificate of Attendance will be available upon request at the Registration Desk.

23

SPEAKERS AND CHAIRPERSONS

J. Ancsin 6

R. Attinkara 8

M. Averna 10

F. Bernini 6

J. Boren 9

L. calabresi 6

A.L. catapano 4

B. Dahlback 6

G. Dallinga-Thie 4

S. Davidson 6

S. Delbosc 10

Y. Feng 7

c. Fernandez-hernando 5

G. Francis 7

R. Frikke-Smith 9

M. Gomaraschi 7

R. hasballa 7

S. hazen 8

G.K. hovingh 10

E. hurt-camejo 5

E. Ikonen 6

D. Kardassis 5

B.A. Kingwell 9

A. Kontush 6

J.A. Kuivenhoven 4

U. Landmesser 7

P.P. Laurila 4

J. Lövgren 4

A. Moschetta 5

J-R. Nofer 10

D. Norata 7

A. Ossoli 6

c. Parolini 10

J. Parks 6

D. Perisa 5

h. Quesada 5

S. Rashid 8

A. Remaley 10

N. Ronda 10

K.A. Rye 8

R. Singaraja 4

U. Tietge 9

A. Tybjaerg-hansen 4

R.J. van der Sluis 7

A. von Eckardstein 9

c. Wadsack  7

T. Weichhart 8

c. Wellington 8

c. Widmann 9

V. Zannis 7

www.ias-hdlworkshop2014.com

SPONSORS